$Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma$

Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma

Bibliographic Details
Main Authors:	Ke Lian, Qiao-Hua Zhang, Shu-Ling Hou, Li Li
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Series:	Asian Journal of Surgery
Subjects:	Non-Hodgkin's lymphoma B-cell lymphoma Relapse Refractory Metronomic chemotherapy Antiangiogenesis therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958422015597

Similar Items

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience
by: Natalia S. Tsaplina, et al.
Published: (2022-11-01)

Metronomic therapy for gynecologic cancers
by: Wen-Hsiang Su, et al.
Published: (2012-06-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Mohammadali Mashhadi, et al.
Published: (2011-09-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Behrooz Najafi, et al.
Published: (2011-10-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
by: Talita Máira Bueno da Silveira da Rocha, et al.

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
by: Artem Gusak, et al.
Published: (2021-11-01)

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
by: Beatrice Casadei, et al.
Published: (2021-09-01)

Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results
by: Natalia S. Tsaplina, et al.
Published: (2023-05-01)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
by: Novakovic Barbara Jezersek
Published: (2015-12-01)

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma
by: Matthias A. Fante, et al.
Published: (2023-05-01)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
by: Shinichi Makita, et al.
Published: (2022-12-01)

ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study
by: Hamdy Zawam, et al.
Published: (2018-06-01)

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
by: Alain Antoine Mina, et al.
Published: (2019-03-01)

Outcome of Pregnancy and Labour in a Patient with Hodgkin’s Lymphoma (Clinical Case)
by: A. A. Borscheva, et al.
Published: (2019-09-01)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
by: Nikhil Yegya-Raman, et al.
Published: (2023-03-01)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
by: Yujie Zhang, et al.
Published: (2022-07-01)

The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/ Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: “A Single-Center Experience”
by: Ali Eser, et al.
Published: (2021-05-01)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
by: Cinzia Pellegrini, et al.
Published: (2016-04-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Management of Relapsed Hodgkin Lymphoma During the Second Trimester of Pregnancy: Case Report
by: Fatih Yaman, et al.
Published: (2023-03-01)

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
by: Eva González Barca
Published: (2022-07-01)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
by: Muhammad Salman Faisal, et al.
Published: (2023-04-01)

Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
by: Birgit Burkhardt, et al.
Published: (2021-04-01)

Gemcitabina e ifosfamida no tratamento do linfoma de Hodgkin refratário ou recidivado após múltiplas terapias Gemcitabine and ifosfamide in the treatment of Hodgkin's lymphoma refractory to or relapsed after multiple therapies
by: Luís Fernando Pracchia, et al.
Published: (2007-12-01)

All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
by: Matthias A. Fante, et al.
Published: (2022-05-01)

High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma
by: José A. Fernández-Gutiérrez, et al.
Published: (2022-12-01)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
by: Michael P. Randall, et al.
Published: (2023-09-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Detection of Asymptomatic Cardiac Metastasis and Successful Salvage Chemotherapy Comprising a Prednisone, Etoposide, Procarbazine, and Cyclophosphamide Regimen in an Elderly Japanese Patient Suffering from a Delayed Recurrence of Diffuse Large B-Cell Lymphoma
by: Keita Tagami, et al.
Published: (2012-01-01)

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
by: Theodoros P. Vassilakopoulos, et al.
Published: (2019-07-01)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
by: Karantanos T, et al.
Published: (2017-05-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Oral etoposide and cyclophosphamide: A low-cost palliative metronomic chemotherapy in advanced pediatric cancers
by: Kiran Kumar, et al.
Published: (2020-01-01)

Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma
by: Yanni Hao, et al.
Published: (2023-06-01)